Accipio Dxg (discontinued)

MaxQ AI, Ltd.

**In January 2022 MaxQ announced the discontinuation of their imaging AI product portfolio.**
Accipio Dxg aids in triaging by case-level identification of suspected intracranial hemorrhage positive finding or absence of ICH.
Product specifications Information source: Vendor
Last updated: Jan. 21, 2022
Product name Accipio Dxg (discontinued)
Company MaxQ AI, Ltd.
Subspeciality Neuro
Modality CT
Disease targeted Intracranial hemorrhage
Key-features Identification and triage of non-contrast head exams without suspected ICHs.
Suggested use Before: adapting worklist order
Data characteristics
Population Stroke and head trauma patients suspicious of intracranial hemorrhage.
Input Adult non-contrast head CT exam
Input format DICOM
Output Triage with notification
Output format DICOM Secondary Capture
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time
Certified, Class IIb , MDD
No or not yet
Market presence
On market since 12-2020
Distribution channels GE, Philips, FujiFilm, IBM, Nuance, Blackford
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing model Pay-per-use, Subscription
Based on Number of installations, Number of analyses
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers